IMCR - Company ID 0001671927
The table below shows Immunocore Holdings plc's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $106.68M | $103.69M | $97.96M | $93.88M | $80.25M | $75.40M |
| Cost of revenue | $434.00K | $513.00K | $1.04M | $831.00K | $448.00K | $1.71M |
| Gross profit | - | - | - | - | - | - |
| R&D | $61.11M | $70.57M | $69.01M | $56.47M | $52.77M | $51.07M |
Immunocore Holdings plc reported annual revenue of $400.02M for fiscal year 2025. That is up 29.0% from $310.20M in fiscal 2024. Over the 5 fiscal years shown, annual revenue grew from $36.48M (FY 2021) to $400.02M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $37.85M |
| $39.78M |
| $42.79M |
| $40.20M |
| $35.53M |
| $38.64M |
| Operating income | $7.28M | -$7.17M | -$14.88M | -$3.62M | -$8.50M | -$16.02M |
| Income tax | $301.00K | $481.00K | $606.00K | $1.06M | -$2.64M | $1.49M |
| Net income | $12.97M | -$177.00K | -$10.30M | $5.02M | $8.74M | -$11.62M |
| EPS (diluted) | $0.25 | $0.00 | -$0.20 | $0.10 | $0.17 | -$0.23 |